Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 21, 2017
Pharmacy Choice - News - Pharmaceutical Development - November 21, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

11/14/17 - CORRECTING and REPLACING Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer
Celsion Corporation, an oncology drug development company, today announced the submission of its Phase I/II clinical trial protocol to the U.S. Food and Drug Administration for GEN-1, the Company s DNA-based immunotherapy for the localized treatment of ovarian cancer. The protocol, developed in conjunction with guidance from the Company s Med
11/14/17 - MyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor
MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, presented results from testing a novel machine learning algorithm intended to identify patients with obstructive hypertrophic cardiomyopathy during a late-breaker session at the American...
11/14/17 - Prometic Reports 2017 Third Quarter Highlights and Financial Results
-Prometic Life Sciences Inc. announced today its unaudited financial results for the quarter and the nine month period ended September 30, 2017. The PDUFA date has been set for plasminogen and PBI-4050 has been cleared to commence the pivotal phase 2/ 3 placebo controlled IPF clinical trial, "said Pierre Laurin, President and Chief Executive Office
11/13/17 - "Compositions and Methods for Immunizing against C. Difficile" in Patent Application Approval Process (USPTO 20170304423)
By a News Reporter-Staff News Editor at Clinical Trials Week A patent application by the inventors Pietrobon, Patricia; Foglia, Ginamarie; De Bruyn, Guy; Gurunathan, Sanjay, filed on July 10, 2017, was made available online on November 2, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent ap
11/13/17 - "New Indication of Cinacalcet Hcl Pharmaceutical Composition for Treating Cancer" in Patent Application Approval Process (USPTO 20170304228)
By a News Reporter-Staff News Editor at Cancer Gene Therapy Week A patent application by the inventors Chen, Chiu-Hung; Chuang, Show-Mei; Way, Tzong-Der; Hsiao, Nai-Wan, filed on October 23, 2015, was made available online on November 2, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent app
11/13/17 - "New Indication of Monobenzone Pharmaceutical Composition for Treating Cancer" in Patent Application Approval Process (USPTO 20170304218)
By a News Reporter-Staff News Editor at Clinical Trials Week A patent application by the inventors Chen, Chiu-Hung; Chuang, Show-Mei; Way, Tzong-Der; Hsiao, Nai-Wan, filed on October 23, 2015, was made available online on November 2, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent applica
11/13/17 - 80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up
ProscaVax is OncBioMune's novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated PSA with the biological adjuvants interleukin-2 and granulocyte-macrophage colony-stimulating factor.. OncBioMune is awaiting additional follow-up data related to our previously disclosed study data.
11/13/17 - Abbott Announces FDA Clearance for its Alinity ci-series Next-generation Diagnostic Systems
By a News Reporter-Staff News Editor at Pharma Business Week Abbott has secured U.S. Food and Drug Administration 510 clearance for its Alinity? ci-series instruments for clinical chemistry and immunoassay diagnostics. "Healthcare systems across the United States are under pressure to deliver better care for patients," said Brian Blaser, execu
11/13/17 - Abeona Management to Present at Multiple Conferences in November
Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the Company s senior management team will participate in the following conferences:. About Abeona: Abeona Therapeutics Inc. is a clinical-stage...
11/13/17 - ACADIA Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 7, 2017
By a News Reporter-Staff News Editor at Clinical Trials Week ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, announced that it will report its financial results for the third quarter ended Septemb
11/13/17 - Acer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Acer Therapeutics Inc., a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today reported financial results for the quarter ended September 30, 2017 and provided an update on the Company s recent corporate developments.
11/13/17 - ACURA PHARMACEUTICALS, INC - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
This discussion and analysis should be read in conjunction with the Company's financial statements and accompanying notes included elsewhere in this Report. Historical operating results are not necessarily indicative of results in future periods. with Oxford Finance LLC, or to obtain a waiver from Oxford Finance LLC for our.
11/13/17 - AERPIO PHARMACEUTICALS, INC. - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion of the financial condition and results of operations of Aerpio Pharmaceuticals, Inc. should be read in conjunction with the financial statements and the notes to those statements included in this Quarterly Report on Form 10 Q for the period ended September 30, 2017. Some of the information contained in this discussion and a
11/13/17 - Aerpio Reports Third Quarter 2017 Financial Results
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the third quarter ended September 30, 2017. As of September 30, 2017, cash and cash equivalents totaled $24.8 million. Research and development expenses for the three months ended Septemb
11/13/17 - Affiliated Hospital of Qingdao University Reports Findings in Clinical Trials and Studies (Therapeutic efficacy and safety of various botulinum toxin...
Affiliated Hospital of Qingdao University Reports Findings in Clinical Trials and Studies. According to news reporting originating in Qingdao, People's Republic of China, by NewsRx journalists, research stated, "No recommended guidelines currently exist for the therapeutic concentration or dose of botulinum toxin type A injected into the muscle to
11/13/17 - Alkahest to Present Clinical Results from PLASMA Study in Patients with Mild to Moderate Alzheimer's Disease at the 10th Clinical Trials on...
By a News Reporter-Staff News Editor at Clinical Trials Week Alkahest, Inc., a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, announced an upcoming oral presentation at the 10th Clinical Trials on Alzheimer's Disease conference. The Principal Investigator, Sharon Sha, M.D., will pres
11/13/17 - Allergan Presented New Phase 3 Data of Ulipristal Acetate in Women with Uterine Fibroids at the American Society for Reproductive Medicine Annual...
By a News Reporter-Staff News Editor at Clinical Trials Week Allergan plc presented new analyses of VENUS II, the second of two pivotal Phase 3 clinical trials evaluating the efficacy and safety of ulipristal acetate, an investigational drug for the treatment of abnormal uterine bleeding in women with uterine fibroids. "For a condition that affe
11/13/17 - Allergan Receives FDA Approval For Label Expansion Of VRAYLAR
WASHINGTON- Allergan plc announced the U.S. FDA has approved the supplemental New Drug Application for VRAYLAR for the maintenance treatment of adults with schizophrenia. VRAYLAR is also approved in the U.S. in adults for the acute treatment of schizophrenia and acute treatment of manic or mixed episodes of bipolar I disorder. The efficacy of VRAYL
11/13/17 - Allergan Receives FDA Approval For Use of VRAYLAR? (cariprazine) in the Maintenance Treatment of Schizophrenia
Allergan plc today announced that the U.S. Food and Drug Administration has approved the supplemental New Drug Application for VRAYLAR? for the maintenance treatment of adults with schizophrenia. VRAYLAR is also approved in the U.S. in adults for the acute treatment of schizophrenia and acute treatment of manic or mixed episodes of bipolar I di
11/13/17 - Alpine Immune Sciences Reports Corporate Update and Third Quarter 2017 Financial Results
Alpine Immune Sciences, Inc., a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today provided a corporate update and reported financial results for the third quarter ended September 30, 2017. The preclinical progress in our platform continues to be encouraging as a growing amount o
11/13/17 - Appili Receives FDA and Health Canada Clearance to Begin Clinical Trials of its Antibiotic Oral Liquid Reformulation
By a News Reporter-Staff News Editor at Pharma Business Week Appili Therapeutics Inc., an anti-infective drug development company, announced that both the US Food and Drug Administration and Health Canada have cleared its IND and CTA clinical investigation applications, respectively, to conduct a clinical trial of ATI-1501, a taste-masked antibio
11/13/17 - Arbutus LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)
Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, announced today that the Company's lipid nanoparticle licensee Alnylam Pharmaceuticals, Inc., announced the grant of an accelerated assessment from the European Medicines Agency for patisiran, an investigational RNAi therapeutic being developed...
11/13/17 - Array BioPharma Reports Initial Results From Novel Immunotherapy Combination At The Society For Immunotherapy Of Cancer (SITC) 32nd Annual Meeting
Array BioPharma Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule cancer therapies, today announced data from the Phase 1 b clinical trial evaluating the immunotherapy combination of ARRY-382, with Merck's KEYTRUDA , an anti-PD-1 antibody, in patients with certain advanced s
11/13/17 - Audentes Therapeutics Announces MHRA Approval of Clinical Trial Authorisation Application for AT342 to Treat Crigler-Najjar Syndrome
Audentes Therapeutics, Inc., a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that the Medicines and Healthcare Products Regulatory Agency has approved the Clinical Trial Authorisation application for AT342, the Company's gene.
11/13/17 - AZTherapies, Inc. appoints Karen Reeves, MD as President and Chief Medical Officer
By a News Reporter-Staff News Editor at Pharma Business Week Former Pfizer executive joins AZTherapies focused on Alzheimer's Disease, ischemic stroke, and other neurological diseases by creating novel treatments for neurodegeneration and neuroinflammation. "Dr. Reeves brings tremendous experience in over twenty years in big pharma and provides.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415